10-Q: Denali Therapeutics Reports Second Quarter 2024 Results, Strategic Shift in Pipeline

Denali Therapeutics reports a net loss for Q2 2024, alongside a strategic divestiture of preclinical small molecule programs and a focus on TV-enabled platforms.

Summary

• Denali Therapeutics reported a net loss of $99 million for the second quarter of 2024, compared to a net income of $183.4 million for the same period in 2023, which was primarily due to a large collaboration revenue recognition in 2023.
• The company divested its preclinical small molecule portfolio in March 2024, focusing on its Transport Vehicle (TV)-enabled platforms for brain delivery of large molecules.
• A collaboration and development funding agreement was executed in January 2024, providing up to $75 million for a Phase 2a study of BIIB122/DNL151 in Parkinson's disease.
• Denali completed enrollment in its Phase 1/2 open-label study of tividenofusp alfa in MPS II, and received positive feedback from the FDA regarding a potential accelerated approval pathway.
• The company's cash, cash equivalents, and marketable securities totaled $1.35 billion as of June 30, 2024.
• Research and development expenses decreased to $91.4 million in Q2 2024 from $97.5 million in Q2 2023, primarily due to the divestiture of the preclinical small molecule programs and decreased personnel costs.
• The company recognized a gain of $14.5 million from the divestiture of its preclinical small molecule programs.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments such as the funding agreement and FDA feedback, the net loss, clinical trial setbacks, and termination of the Biogen license temper the overall outlook. The strategic shift is a positive long-term move, but the short-term results are concerning.

Positives

• The company secured a significant funding agreement for the BIIB122/DNL151 program, which will help advance the clinical development of this important asset.
• The FDA's openness to discussing an accelerated approval pathway for tividenofusp alfa in MPS II is a positive development that could expedite the drug's availability to patients.
• The company has a strong cash position of $1.35 billion, which provides financial flexibility to support its ongoing research and development activities.
• The divestiture of the preclinical small molecule portfolio allows the company to focus on its core TV-enabled platform and clinical programs.
• The company completed enrollment of 47 participants with MPS II in the Phase 1/2 open-label study.

Negatives

• The company reported a net loss of $99 million for Q2 2024, a significant decrease compared to the net income of $183.4 million in Q2 2023.
• The Phase 2 HIMALAYA study evaluating SAR443820/DNL788 in participants with ALS did not meet its primary endpoint.
• The company voluntarily paused Part B in the TAK-594/DNL593 Phase 1/2 study in participants with FTD-GRN to implement protocol modifications.
• Biogen terminated its license to the ATV:Abeta program, resulting in the loss of potential future milestone and royalty payments.

Risks

• The company's reliance on third parties for manufacturing and clinical trials poses risks to the timely and successful development of its product candidates.
• The regulatory approval process is lengthy and uncertain, and there is no guarantee that any of the company's product candidates will receive approval.
• The company faces significant competition in the biopharmaceutical industry, which could limit its ability to commercialize its product candidates successfully.
• The company's financial performance is subject to fluctuations in collaboration revenue and the success of its research and development programs.
• The company may need to raise additional capital in the future, which could dilute existing stockholders or impose restrictive covenants.

Future Outlook

The company plans to initiate a Phase 2a study of BIIB122/DNL151 in 2024 and expects Phase 1/2 biomarker and safety data for DNL126 by the end of 2024. Denali will provide an update in 2H 2024 regarding its intention to file for approval of tividenofusp alfa using the accelerated approval pathway.

Management Comments

• The company is prioritizing its TV-enabled platforms for brain delivery of large molecules.
• The company is actively engaged in discussions with health authorities regarding the potential use of biomarkers as primary clinical endpoints to support faster paths to approval.

Industry Context

The strategic shift towards TV-enabled platforms reflects a broader industry trend towards developing more effective therapies for neurodegenerative diseases by improving drug delivery to the brain. The divestiture of the preclinical small molecule portfolio is a move to focus on core competencies and potentially higher-value assets. The termination of the Biogen ATV:Abeta program license highlights the challenges and risks associated with drug development in this space, and the need for companies to adapt to changing clinical data and market conditions.

Comparison to Industry Standards

• Denali's focus on TV-enabled platforms aligns with the industry's increasing interest in overcoming the blood-brain barrier, a major hurdle in treating neurological disorders. Companies like Biohaven and Cerevel Therapeutics are also exploring novel approaches to CNS drug delivery.
• The divestiture of the preclinical small molecule portfolio is a strategic move similar to what other biopharma companies have done to streamline operations and focus on core assets. For example, companies like AbbVie and Biogen have divested certain programs to focus on their core therapeutic areas.
• The collaboration and development funding agreement for BIIB122/DNL151 is a common approach in the industry, where companies share the risk and cost of drug development. Similar collaborations exist between companies like Roche and Ionis, and Novartis and Voyager.
• The FDA's openness to discussing an accelerated approval pathway for tividenofusp alfa is a positive sign, as it reflects the agency's willingness to expedite the development of therapies for rare diseases. This is similar to the accelerated approval pathways granted to other rare disease therapies, such as Sarepta Therapeutics' Exondys 51 for Duchenne muscular dystrophy.
• The failure of the Phase 2 HIMALAYA study for SAR443820/DNL788 in ALS is a reminder of the high failure rate in clinical trials, particularly in neurodegenerative diseases. This is consistent with the industry's experience, where many promising drug candidates fail to meet their primary endpoints in late-stage trials.

Related Party Transactions

• Includes related-party collaboration revenue from customers of $294.1 million and $294.3 million for the three and six months ended June 30, 2023, respectively.
• Includes expenses for cost sharing payments due to a related party of $7.0 million and $11.1 million for the three and six months ended June 30, 2023, respectively.

Stakeholder Impact

• Shareholders may be concerned about the net loss and the termination of the Biogen license, but may be encouraged by the strategic shift and the funding agreement.
• Employees may be affected by the divestiture of the preclinical small molecule portfolio, but may be motivated by the focus on core programs.
• Patients with MPS II may benefit from the potential accelerated approval of tividenofusp alfa.
• Patients with Parkinson's disease may benefit from the Phase 2a study of BIIB122/DNL151.
• Customers and suppliers may be affected by the strategic shift and the divestiture of the preclinical small molecule portfolio.

Next Steps

• The company plans to initiate a Phase 2a study of BIIB122/DNL151 in 2024.
• The company expects Phase 1/2 biomarker and safety data for DNL126 by the end of 2024.
• The company will provide an update in 2H 2024 regarding its intention to file for approval of tividenofusp alfa using the accelerated approval pathway.

Key Dates

Keywords

Denali Therapeutics, Neurodegenerative Diseases, Lysosomal Storage Diseases, Transport Vehicle, Blood-Brain Barrier, Clinical Trials, Biopharmaceutical, Tividenofusp alfa, BIIB122/DNL151, DNL343, SAR443820/DNL788, DNL126, TAK-594/DNL593, MPS II, Parkinson's Disease, ALS, Multiple Sclerosis, Alzheimer's Disease, FTD-GRN